) The purpose of this Clinical Oncology Research Career Development Program is to ensure career development of clinical investigators who can conduct innovative hypothesis-driven research in the clinic and community. In an era when advances in the laboratory are accelerating more rapidly than advances in the clinic, successful clinical investigators must not only conduct clinical trials, but also understand and utilize new biology to develop innovative strategies for cancer treatment, detection and prevention. Thus, successful clinical investigators must be able to collaborate with colleagues in the laboratory and in other clinical disciplines, as well as in the public and private sectors. Awardees must have a junior faculty position and be board-certified or board-eligible in any of the clinical oncology disciplines, including surgical, gynecologic, medical, pediatric, or radiation oncology. Individuals who have excelled in their clinical training and have a clear commitment to academic oncology, as evidenced by previous publications and a credible plan for career development, will be considered. Particular attention will be given to recruitment of talented investigators of both genders and of under-represented ethnic groups. Training activities will include participation in the curriculum provided by a K30 Clinical Research Curriculum award and additional course work, generally leading to an M.S. degree in clinical investigation or an M.P.H. degree in community-based research. Opportunities will be provided for externships at FDA and leading biopharmaceutical companies. Each trainee will complete multiple projects mentored by one or more senior faculty with a track record for conducting hypothesis-driven clinical or community-based research with a strong translational component, often in collaboration with investigators from other disciplines. Each trainee will be expected to publish multiple papers in respected journals and attain peer-reviewed funding. Awardees will be supported for two to five years with annual renewal based on progress toward defined goals. Dr. Robert Bast will lead the overall program in collaboration with Dr. James Cox (clinical investigation) and Dr. Robert Chamberlain (community-based research). An Advisory Committee of senior leaders in the relevant clinical disciplines will advise the Program Leader on all matters of policy, select awardees, and monitor their progress. Support is requested for 4 junior faculty clinical oncologists annually.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA088084-05
Application #
6804068
Study Section
Special Emphasis Panel (ZCA1-GRB-N (M1))
Program Officer
Lei, Ming
Project Start
2000-09-13
Project End
2005-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
5
Fiscal Year
2004
Total Cost
$538,920
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Yu; Zoltan, Michelle; Riquelme, Erick et al. (2018) Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology 155:210-223.e3
Unver, Nese; McAllister, Florencia (2018) IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev 41:10-17
Pal, Navdeep; Broaddus, Russell R; Urbauer, Diana L et al. (2018) Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol 131:109-116
Grossberg, Aaron J; Mohamed, Abdallah S R; Elhalawani, Hesham et al. (2018) Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data 5:180173
Multidisciplinary Larynx Cancer Working Group; Mulcahy, Collin F; Mohamed, Abdallah S R et al. (2018) Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck 40:2060-2069
Armbruster, Shannon D; Sun, Charlotte C; Westin, Shannon N et al. (2018) Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol 149:484-490
Reddy, S M; Barcenas, C H; Sinha, A K et al. (2018) Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118:17-23
Loree, Jonathan M; Pereira, Allan A L; Lam, Michael et al. (2018) Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res 24:1062-1072
Ikoma, Naruhiko; Roland, Christina L; Cormier, Janice N et al. (2018) Nongastrointestinal Stromal Tumor Spindle Cell Sarcomas of the Colon or Rectum. Am Surg 84:570-575
Gopalakrishnan, V; Spencer, C N; Nezi, L et al. (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97-103

Showing the most recent 10 out of 210 publications